Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

Prior treatment

• Patients who have a contraindication to the drug according to the country-specific prescribing information label.
• Prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day.
  • NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Other illness

• Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other co-morbidities that can predictably prevent the patient from adequately completing the schedule of visits and assessments.

• Male or female, 12 years of age or older at the baseline visit. NOTE: Adolescent patients (at least 12 years old, but less than 18 years) are eligible in the US or Canada only after DUPIXENT receives the respective country's regulatory approval for use in this age group.
• Initiating treatment with DUPIXENT® as standard-of-care for AD according to the country-specific prescribing information (Note: Participants will be screened when they received their initial prescription for DUPIXENT®).
• Willing and able to comply with study-related activities.
• Able to understand and complete study-related questionnaires.
• Provide signed informed consent or parental/legal guardian consent plus patient assent, where applicable.